Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. That said, here are three unprofitable companiesto avoid and some better opportunities instead.
Amplitude (AMPL)
Trailing 12-Month GAAP Operating Margin: -27.8%
Born from the realization that companies were flying blind when it came to understanding user behavior in their digital products, Amplitude (NASDAQ: AMPL) provides a digital analytics platform that helps businesses understand how people use their digital products to improve user experiences and drive revenue growth.
Why Are We Wary of AMPL?
- Customers generally do not adopt complementary products as its 104% net revenue retention rate lags behind the industry standard
- Poor expense management has led to operating margin losses
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
At $12.56 per share, Amplitude trades at 3.6x forward price-to-sales. Read our free research report to see why you should think twice about including AMPL in your portfolio.
Optimum Communications (OPTU)
Trailing 12-Month GAAP Operating Margin: -35.3%
Based in Long Island City, Optimum Communications (NYSE: OPTU) is a telecommunications company offering cable, internet, telephone, and television services across the United States.
Why Do We Steer Clear of OPTU?
- Sluggish trends in its broadband subscribers suggest customers aren’t adopting its solutions as quickly as the company hoped
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
- High net-debt-to-EBITDA ratio of 8× increases the risk of forced asset sales or dilutive financing if operational performance weakens
Optimum Communications is trading at $0.85 per share, or 7.7x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than OPTU.
Moderna (MRNA)
Trailing 12-Month GAAP Operating Margin: -149%
Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ: MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.
Why Should You Sell MRNA?
- Sales tumbled by 20.5% annually over the last five years, showing market trends are working against it during this cycle
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 24.5% annually, worse than its revenue
- Free cash flow margin dropped by 95.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up
Moderna’s stock price of $60.33 implies a valuation ratio of 11.6x forward price-to-sales. If you’re considering MRNA for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
